As for GLP-1 RAs, Buse et al demonstrated that 2 years exenatide therapy was associated with significant improvement in abnormal liver transaminases, biomarkers of hepatocyte injury most commonly reflecting NAFLD [26]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.